Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Characterization of (S)-Des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a Selective High-Affinity Radioligand for 5-Hydroxytryptamine3 Receptors

William A. Hewlett, Bakula L. Trivedi, Zhang-Jin Zhang, Tomas de Paulis, Dennis E. Schmidt, David M. Lovinger, M. Sib Ansari and Michael H. Ebert
Journal of Pharmacology and Experimental Therapeutics January 1999, 288 (1) 221-231;
William A. Hewlett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bakula L. Trivedi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhang-Jin Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas de Paulis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis E. Schmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Lovinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Sib Ansari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Ebert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The 5-hydroxytryptamine(HT)3 receptor subtype is present in the central nervous system (CNS) in low abundance, and few selective radiolabeled antagonists with high specific activity are available to study these sites. DAIZAC [desamino-3-iodo-(S)-zacopride; (S)-5-chloro-3-iodo-2-methoxy-N-(1-azobicyclo-[2.2.2]oct-3-yl)benzamide] is a compound with high affinity and selectivity for the 5-HT3 receptor. Scatchard analysis of specific binding to NCB-20 cell membranes gave a Bmax of 340 ± 58 fmol/mg protein and a KD of 0.14 ± 0.03 nM, which is in agreement with the value previously reported in rat brain (KD = 0.15 nM). Nonspecific binding of [125I]DAIZAC in NCB-20 cells was <1% of total binding at the KD for DAIZAC compared with 17% in the rat brain preparation. Unlabeled DAIZAC (10 μM) showed minimal ability to displace binding of radiolabeled ligands selected for their affinities for other CNS receptor and uptake carrier binding sites. The discrimination ratio of DAIZAC for the 5-HT3 receptor over the M1 muscarinic binding site, the non-5-HT3 site at which it was most potent, was >2800. Serotonergic antagonists at every other known CNS serotonergic binding sites (3–30 μM) were ineffective in displacing [125I]DAIZAC binding in rat brain membranes. Similarly, antagonists (3–30 μM) for other nonserotonergic receptors and uptake sites were ineffective in displacing [125I]DAIZAC binding. Autoradiographic studies showed highest specific binding in area postrema and nucleus solitarius, with intermediate levels of binding in entorhinal cortex and hippocampus. DAIZAC inhibited 5-HT3 receptor-mediated inward cation current in NCB-20 cells with an IC50 of 0.24 nM. [125I]DAIZAC is a potent and highly selective ligand for in vitro studies of the 5-HT3 receptor.

Footnotes

  • Send reprint requests to: Dr. William A. Hewlett, Department of Psychiatry, A-2207, Vanderbilt University Medical Center, Nashville TN 37232.

  • ↵1 This work was supported by the Obsessive-Compulsive Disorder/Tourette Program and the Department of Psychiatry, Vanderbilt University School of Medicine (Nashville, TN). We also acknowledge the Neuropharmacology and Drug Development Program under the direction of Dr. L. Brady (Division of Neuroscience and Behavioral Science, National Institute of Mental Health) for generous support in underwriting the cost of the NOVASCREEN assays.

  • Abbreviations:
    CNS
    central nervous system
    DAIZAC
    desamino-3-iodo-(S)-zacopride
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    5-HT
    5-hydroxytryptamine
    • Received April 22, 1998.
    • Accepted August 5, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 288 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 288, Issue 1
1 Jan 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of (S)-Des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a Selective High-Affinity Radioligand for 5-Hydroxytryptamine3 Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of (S)-Des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a Selective High-Affinity Radioligand for 5-Hydroxytryptamine3 Receptors

William A. Hewlett, Bakula L. Trivedi, Zhang-Jin Zhang, Tomas de Paulis, Dennis E. Schmidt, David M. Lovinger, M. Sib Ansari and Michael H. Ebert
Journal of Pharmacology and Experimental Therapeutics January 1, 1999, 288 (1) 221-231;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Characterization of (S)-Des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a Selective High-Affinity Radioligand for 5-Hydroxytryptamine3 Receptors

William A. Hewlett, Bakula L. Trivedi, Zhang-Jin Zhang, Tomas de Paulis, Dennis E. Schmidt, David M. Lovinger, M. Sib Ansari and Michael H. Ebert
Journal of Pharmacology and Experimental Therapeutics January 1, 1999, 288 (1) 221-231;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Effects of Antidepressants and Benzodiazepine-Type Anxiolytic Agents on Hepatic Porphyrin Accumulation in Primary Cultures of Chick Embryo Liver Cells
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics